Psilera Collaborates with Drug Development Leader Hesperos to Advance Preclinical Modeling of PSIL-006 for Frontotemporal DementiaStrategic agreement underscores Psilera's commitment to advancing PSIL-006 with precision neurology approachResults are expected in...

FOR IMMEDIATE RELEASE Cloud 9 Care™ Awarded U.S. Patent for Groundbreaking Pressure Injury Prevention System Hillsboro, OR — May 6, 2025 —  Cloud 9 Care, a nurse-led healthcare innovation company, today...

FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other DrugsFor Immediate Release:April 10, 2025Today, the U.S. Food and Drug Administration is taking a groundbreaking step...

Pretzel Therapeutics Initiates Phase 1 Clinical Study Evaluating PX578, Lead Therapeutic in its Bioenergetics Restoration Franchise- First-in-class approach to targeting mitochondrial DNA polymerase (POLG) with disease modifying potential across mitochondrial...

Medtronic reports first-ever procedures with next-gen PillCam Genius capsule endoscopy kitDecember 12, 2024 By Sean WhooleyMedtronic(NYSE: MDT)+ today announced the first-ever patient procedure ingestion using its next-generation PillCam Genius SB capsule endoscopy kit. The...

Hesperos and UCF Researchers Develop Human iPSC-Derived Myelination Model, Enabling Investigation and Treatment Development for Peripheral Nervous System DiseasesOctober 24, 2024 04:39 PM Eastern Daylight TimeORLANDO, Fla.--(BUSINESS WIRE)--Hesperos, a leader...

Landmark Phase 2 study demonstrates the first successful clinical application of antifibrotic therapy for breast cancer News provided byMeCo Diagnostics Oct 17, 2024, 12:43 ET Positive study enables valuable repositioning of new antifibrotic...

Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive...

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity TestingThe potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globallyAugust 08, 2024 08:45 ET| Source: Oragenics SARASOTA, Fla.,...

Cognigenics Announces Groundbreaking Publication on shRNA Treatment for 5-HT2A Receptor KnockdownAugust 05, 2024 08:45 AM Eastern Daylight TimeSTUART, Fla.--(BUSINESS WIRE)--Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and...